Luke Timmerman on Muck Rack

Luke Timmerman

Verified
Seattle
As seen in: TIME, The Long Run with Luke Timmerman, Timmerman Report, Forbes, The Seattle Times, STAT, BioXconomy, a16z, UNDARK, Kirkus Reviews, Informa Connect, Biotechnology Innovation Organization, Libro.fm Blog and
Biotech journalist. Founder @TimmermanReport.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Luke

Contact Luke, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Precision Cancer Drugs and Combos: Troy Wilson on The Long Run

|
By Luke Timmerman Verified
| Timmerman Report
Troy Wilson is today’s guest on The Long Run. Troy is the co-founder and CEO of San Diego-based Kura Oncology. The company, founded in 2014, has gone all the way through R&D to develop its own novel cancer drug. It’s called ziftomenib (brand name Komzifti). It’s an oral pill that inhibits a target called menin.
Open in Who Shared Issue with article?

The Rise, Fall, and Rise (and Fall…?) of Cell and Gene Therapy

|
By Carl M. Schoellhammer, Luke Timmerman Verified
| Timmerman Report
Carl Schoellhammer, partner, DeciBio More than $14 billion in announced acquisition value has flowed into in vivo cell therapy companies over the last 18 months. Lilly acquired Kelonia, AbbVie bought Capstan, BMS acquired Orbital, and AstraZeneca bought EsoBiotec, to name a few.
Open in Who Shared Issue with article?

AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead

|
By Luke Timmerman Verified
| Timmerman Report
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Open in Who Shared Issue with article?
See all 1,312 licensed articles (1,355 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified